NASDAQ
Esperion Therapeutics, Inc. (ESPR) has a free cash flow growth of -161.43% as of Friday, May 29, 2026. This represents a 151.96% decrease compared to its 12-month average of 310.69%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.